<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03664973</url>
  </required_header>
  <id_info>
    <org_study_id>Serratus GC</org_study_id>
    <nct_id>NCT03664973</nct_id>
  </id_info>
  <brief_title>Serratus Plane Block for Rib Fractures</brief_title>
  <official_title>Effect of the Serratus Plane Block on the Outcome in Patient With Multiple Rib Fractures: A Prospective, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcispedale Santa Maria Nuova-IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcispedale Santa Maria Nuova-IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with ipsilateral multiple rib fractures will be randomized to receive either a
      single-shot ultrasound-guided serratus plane block, or a continuous serratus plane block
      within 24h from the chest trauma. Primary outcome is the difference in forced respiratory
      volume (FEV1) at 72h.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients admitted in emergency department with a chest trauma and ipsilateral multiple rib
      fractures, will be randomized as described above. All patients will receive the serratus
      block with a ropivacaine 0.37% solution 20 ml. Then, they will randomized to receive either a
      peripheral catheter placed above the 5th rib on the middle axillary line, or nothing. In all
      patients postoperative analgesia also include Paracetamol 1g IV each 6h and a patient
      controlled analgesia (PCA) of morphine set out as follow: bolus 1 mg, loch out 15 min, max 4
      boluses each hour. In all patients an arterial blood sample for gas analysis and a FEV1 will
      be achieved before the block, after 1 hour and at 72h.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2018</start_date>
  <completion_date type="Anticipated">October 3, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary change function</measure>
    <time_frame>day 0 and day 3</time_frame>
    <description>FEV 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numerical rating scale (NRS) of pain</measure>
    <time_frame>day 0, day 1, day 2, day 3, day 4</time_frame>
    <description>Pain both at rest and on movement on a 0-10 scale where 0 is the best and 10 the worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphine</measure>
    <time_frame>day 0, day 1, day 2, day 3, day 4</time_frame>
    <description>morphine requirement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital stay</measure>
    <time_frame>day 1, day 2, day 3, day 4, day 5, day 6, day7</time_frame>
    <description>time to fill the discharge criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chest Trauma</condition>
  <condition>Chest Pain</condition>
  <arm_group>
    <arm_group_label>continuous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>continuous local anesthetic infusion (ropivacaine 0.2%)on the serratus plane for at least 72h adds to a Single-shot serratus plane block with ropivacaine 0.37% solution 20 ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single-shot</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single-shot serratus plane block with ropivacaine 0.37% solution 20 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Serratus plane block</intervention_name>
    <description>Local anesthetic infusion though a peripheral nerve catheter placed on the 5th rib under the serratus plane</description>
    <arm_group_label>continuous</arm_group_label>
    <arm_group_label>single-shot</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2 o more ipsilateral rib fractures

          -  Trauma within 24h from hospital admission

          -  Informed consent

        Exclusion Criteria:

          -  Chest drain

          -  head trauma

          -  bilateral rib fractures

          -  Intensive care admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>gianluca cappelleri</last_name>
    <phone>+390522296386</phone>
    <email>gianluca.cappelleri@ausl.re.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>gianluca cappelleri</last_name>
    <email>gianluca.cappelleri@ausl.re.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AUSL IRCCS Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42120</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>gianluca cappelleri, MD</last_name>
      <email>gianluca.cappelleri@ausl.re.it</email>
    </contact>
    <contact_backup>
      <last_name>gianluca cappelleri, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 2, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2018</study_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chest Pain</mesh_term>
    <mesh_term>Rib Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

